Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.NN
Abstract
Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients. In this secondary analysis of data from the CONFIRMS trial, we found that among 374 older subjects, urate-lowering therapy with approved doses of febuxostat or commonly prescribed doses of allopurinol was at least comparable to that in 1894 younger subjects and was well tolerated despite high rates of renal impairment and cardiovascular comorbidities in the older subjects.
Links
MeSH
Pub Type(s)
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
22132950
Clinical Trial Links
Citation
Becker, Michael A., et al. "Treating Hyperuricemia of Gout: Safety and Efficacy of Febuxostat and Allopurinol in Older Versus Younger Subjects." Nucleosides, Nucleotides & Nucleic Acids, vol. 30, no. 12, 2011, pp. 1011-7.
Becker MA, MacDonald PA, Hunt B, et al. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011-7.
Becker, M. A., MacDonald, P. A., Hunt, B., & Gunawardhana, L. (2011). Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides, Nucleotides & Nucleic Acids, 30(12), 1011-7. https://doi.org/10.1080/15257770.2011.603715
Becker MA, et al. Treating Hyperuricemia of Gout: Safety and Efficacy of Febuxostat and Allopurinol in Older Versus Younger Subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011-7. PubMed PMID: 22132950.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
AU - Becker,Michael A,
AU - MacDonald,Patricia A,
AU - Hunt,Barbara,
AU - Gunawardhana,Lhanoo,
PY - 2011/12/3/entrez
PY - 2011/12/3/pubmed
PY - 2012/3/22/medline
SP - 1011
EP - 7
JF - Nucleosides, nucleotides & nucleic acids
JO - Nucleosides Nucleotides Nucleic Acids
VL - 30
IS - 12
N2 - Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients. In this secondary analysis of data from the CONFIRMS trial, we found that among 374 older subjects, urate-lowering therapy with approved doses of febuxostat or commonly prescribed doses of allopurinol was at least comparable to that in 1894 younger subjects and was well tolerated despite high rates of renal impairment and cardiovascular comorbidities in the older subjects.
SN - 1532-2335
UR - https://www.unboundmedicine.com/medline/citation/22132950/Treating_hyperuricemia_of_gout:_safety_and_efficacy_of_febuxostat_and_allopurinol_in_older_versus_younger_subjects_
L2 - https://www.tandfonline.com/doi/full/10.1080/15257770.2011.603715
DB - PRIME
DP - Unbound Medicine
ER -